at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Company profile
Ticker
STRO
Exchange
Website
CEO
William Newell
Employees
Location
Fiscal year end
Industry (SIC)
Former names
Fundamental Applied Biology Inc, SUTRO BIOPHARMA INC
SEC CIK
Corporate docs
IRS number
452441988
STRO stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
8-K
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
2 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
25 Mar 24
S-8
Registration of securities for employees
27 Feb 24
8-K
Other Events
9 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
27 Nov 23
Latest ownership filings
4
Venkatesh Srinivasan
12 Apr 24
SC 13G
Point72 Asset Management, L.P.
5 Apr 24
4/A
WILLIAM J NEWELL
22 Mar 24
4/A
LINDA A FITZPATRICK
22 Mar 24
4/A
EDWARD C ALBINI
22 Mar 24
4
LINDA A FITZPATRICK
7 Mar 24
4
Venkatesh Srinivasan
7 Mar 24
4
WILLIAM J NEWELL
7 Mar 24
4
Hans-Peter Gerber
7 Mar 24
4
Jane Chung
7 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 82.71 mm | 82.71 mm | 82.71 mm | 82.71 mm | 82.71 mm | 82.71 mm |
Cash burn (monthly) | 51.09 mm | 1.25 mm | 15.82 mm | 16.04 mm | 11.17 mm | 12.46 mm |
Cash used (since last report) | 348.94 mm | 8.51 mm | 108.02 mm | 109.57 mm | 76.28 mm | 85.12 mm |
Cash remaining | -266.24 mm | 74.20 mm | -25.32 mm | -26.86 mm | 6.43 mm | -2.42 mm |
Runway (months of cash) | -5.2 | 59.6 | -1.6 | -1.7 | 0.6 | -0.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 112 |
Opened positions | 7 |
Closed positions | 19 |
Increased positions | 44 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 190.94 bn |
Total shares | 63.90 mm |
Total puts | 1.10 k |
Total calls | 1.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 5.99 mm | $20.77 bn |
Suvretta Capital Management | 5.88 mm | $20.42 bn |
Biotechnology Value Fund L P | 3.35 mm | $0.00 |
BVF | 3.35 mm | $11.62 bn |
Rubric Capital Management | 3.34 mm | $11.61 bn |
Adage Capital Partners GP, L.L.C. | 3.11 mm | $10.77 bn |
Vanguard | 2.87 mm | $9.95 bn |
BEN Franklin Resources | 2.83 mm | $9.84 bn |
Verition Fund Management | 2.50 mm | $8.68 bn |
Holocene Advisors | 2.13 mm | $7.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Venkatesh Srinivasan | Common Stock | Payment of exercise | Dispose F | No | No | 4.5 | 7,582 | 34.12 k | 30,122 |
11 Apr 24 | Venkatesh Srinivasan | Common Stock | Option exercise | Acquire M | No | No | 0 | 21,250 | 0.00 | 37,704 |
11 Apr 24 | Venkatesh Srinivasan | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 21,250 | 0.00 | 42,500 |
7 Mar 24 | Fitzpatrick Linda A | RSU Common Stock | Grant | Acquire A | No | No | 0 | 16,500 | 0.00 | 16,500 |
7 Mar 24 | Fitzpatrick Linda A | Stock Option (Right to Buy Common Stock) Common Stock | Grant | Acquire A | No | No | 4.8 | 22,000 | 105.60 k | 22,000 |
5 Mar 24 | Fitzpatrick Linda A | Common Stock | Payment of exercise | Dispose F | No | No | 4.54 | 3,108 | 14.11 k | 72,952 |
5 Mar 24 | Fitzpatrick Linda A | Common Stock | Option exercise | Acquire M | No | No | 0 | 8,750 | 0.00 | 76,060 |
5 Mar 24 | Fitzpatrick Linda A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 8,750 | 0.00 | 8,750 |
5 Mar 24 | Fitzpatrick Linda A | RSU Common Stock | Grant | Acquire A | No | No | 0 | 28,500 | 0.00 | 28,500 |
5 Mar 24 | Fitzpatrick Linda A | Stock Option (Right to Buy Common Stock) Common Stock | Grant | Acquire A | No | No | 4.54 | 38,000 | 172.52 k | 38,000 |
News
Piper Sandler Reiterates Overweight on Sutro Biopharma, Lowers Price Target to $11
3 Apr 24
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
3 Apr 24
Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18
3 Apr 24
JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
3 Apr 24
What's Going On With Sutro Biopharma (STRO) Stock?
2 Apr 24
Press releases
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
2 Apr 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
25 Mar 24